**Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome**

Ruben A. T. Mars#1, Yi Yang#2, Tonya Ward3, Mo Houtti4,Sambhawa Priya5, Heather R. Lekatz1, Xiaojia Tang6, Zhifu Sun6, Krishna R. Kalari6, Tal Korem7,8, Yogesh Bhattarai1, Tenghao Zheng9, Noam Bar10, Gary Frost2, Abigail J. Johnson3, Will van Treuren11, Shuo Han11, Tamas Ordog12, Madhusudan Grover1,12, Justin Sonnenburg11, Mauro D’Amato9, Michael Camilleri1,12, Eran Elinav13,14, Eran Segal10, Ran Blekhman4, Gianrico Farrugia1,12, Jonathan R. Swann2,15, Dan Knights\*3,4, Purna C. Kashyap\*$1,12

# Equally contributing first authors

\* Equally contributing corresponding authors

$ Lead contact

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905, USA

2Department of Metabolism, Digestion and Reproduction, Imperial College, London, SW7 2AZ, UK

3BioTechnology Institute, College of Biological Sciences, University of Minnesota, Minneapolis, MN, 55455, USA

4Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN, 55455, USA

5Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN, 55455, USA

6Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA

7Department of Systems Biology, Columbia University, New York, NY, 10032, USA

8CIFAR Azrieli Global Scholars program, CIFAR, Toronto, ON, M5G 1M1, Canada

9School of Biological Sciences, Monash University, Clayton, 3800, VIC, Australia

10Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, 76100, Israel

11Department of Microbiology and Immunology, Center for Human Microbiome Studies, Stanford University, Stanford, CA, 94305, USA

12Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, 55905, USA

13Department of Immunology, Weizmann Institute of Science, Rehovot, 76100, Israel

14Division of Cancer-Microbiome Research, DKFZ, 69120, Heidelberg, Germany

15School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, SO17 1BJ, UK

Address correspondence to:

Purna Kashyap, MBBS, AGAF

Associate Professor

Department of Medicine and Physiology and Biomedical Engineering

Consultant, Division of Gastroenterology and Hepatology

Mayo Clinic, Rochester, MN, USA 55905

Email: [kashyap.purna@mayo.edu](mailto:Kashyap.purna@mayo.edu)

Phone: 507-284-2478

Dan Knights, PhD

Associate Professor

Biotechnology Institute

Department of Computer Science and Engineering

University of Minnesota, Minneapolis, MN, USA 55455

Email: [dknights@umn.edu](mailto:dknights@umn.edu)

Phone: 612-564-2762

**Summary (148/150 words)**

The gut microbiome has been implicated in multiple human chronic gastrointestinal (GI) disorders. Determining its mechanistic role in disease has been difficult due to apparent disconnects between animal and human studies and lack of an integrated multi-omics view of disease-specific physiological changes. We integrated longitudinal multi-omics data from the gut microbiome, metabolome, host epigenome, and transcriptome in the context of irritable bowel syndrome (IBS) host physiology. We identified IBS subtype-specific and symptom-related variation in microbial composition and function. A subset of identified changes in microbial metabolites correspond to host physiological mechanisms that are relevant to IBS. By integrating multiple data layers, we identified purine metabolism as a novel host-microbial metabolic pathway in IBS with translational potential. Our study highlights the importance of longitudinal sampling and integrating complementary multi-omics data to identify functional mechanisms that can serve as therapeutic targets in a comprehensive treatment strategy for chronic GI diseases.

**Introduction**

Irritable bowel syndrome (IBS) is a globally prevalent disorder characterized by recurrent abdominal pain or discomfort. IBS is predominantly seen in females and is associated to changes in stool form or frequency, and based on the predominant stool form classified as constipation predominant (IBS-C), diarrhea predominant (IBS-D) or mixed (IBS-M).

IBS pathogenesis involves changes in gastrointestinal motility, intestinal secretion, visceral hypersensitivity, and intestinal permeability, all of which can be modified by the gut microbiome (Bhattarai et al., 2017a). In addition, IBS symptoms are affected by diet, host genetics, and environment, which are also known to modulate the human gut microbiome (Bhattarai et al., 2017a). Experimental evidence supporting a role for the gut microbiome in IBS is based on transplantation experiments, where transit time (De Palma et al., 2017; Touw et al., 2017), pain sensation thresholds (Crouzet et al., 2013), and intestinal permeability (Edogawa et al., 2019) differences associated with IBS-C and IBS-D were replicated in gnotobiotic mice following transplantation of fecal microbiota from patients. However, in the absence of robust animal models mimicking all aspects of IBS pathophysiology, human studies are needed to uncover the interaction of the gut microbiome with relevant human-specific disease pathways.

Human studies in IBS are limited by cross-sectional sampling and lack of subtype stratification, which is reflected in the lack of agreement in findings across the large number of microbiome studies (Duan et al., 2019; Pittayanon et al., 2019). The latter further increases variability given the well-described influence of gastrointestinal transit on the gut microbiome (Kashyap et al., 2013; Roager et al., 2016). In addition, IBS, like other chronic gastrointestinal disorders, is characterized by periods of remission and exacerbation in symptoms, and cross-sectional samples thus fails to account for temporal variability in disease. Finally, inherent differences in host physiology between human and animal studies has been a barrier in advancing our understanding of mechanistic roles for the gut microbiome in IBS.

We performed a longitudinal study in subsets of IBS patients integrating multi-omic measurements including the microbial metagenome, host transcriptome and methylome with assessment of host functions and identified IBS subtype-specific mechanisms driven by altered microbial metabolism which corresponded with concurrent changes in host physiology.

**Results**

This is a prospective observational study using longitudinal multi-omics sampling of microbiome and host samples with the goal of identifying microbial mediators driving subtype-specific phenotypes in IBS. This design allowed us to compare healthy controls (HC) to patients with IBS-C or IBS-D (Rome III criteria). We matched study participants for gender, age and body mass index (BMI); further inclusion and exclusion criteria are outlined in **Methods**. A total of 77 participants provided stool samples for at least one time point, and 42 participants agreed to undergo flexible sigmoidoscopy allowing us to obtain colonic biopsies longitudinally. Sample types and demographics of study subjects, as well as extensive metadata including medication use, hospital anxiety and depression score, and IBS symptom severity score (SSS), are outlined in **Figure 1A**-**C, Figure S1A** and **Table S1**. Study subjects provided dietary recall (**Table S1**) and symptom severity at each visit. IBS patients were given the option to provide an additional stool sample and complete symptom severity questionnaire between regular visits at the time of a self-identified flare, which was defined as a substantial worsening of symptoms between visits. A total of 12 subjects provided the additional stool sample at the time of flare (6 each for IBS-C and IBS-D).

To identify microbial drivers of subtype-specific symptoms in IBS, we performed shotgun metagenomic sequencing and metabolomics on stool samples, metabolomics and cytokine measurements on serum samples, and 16S rRNA gene sequencing, metabolome, transcriptome and methylome analyses on biopsy samples (**Figure 1A** and **Methods**).

***Longitudinal sampling overcomes heterogeneity seen in cross-sectional microbiome studies***

A cross-sectional study of the gut microbiome in chronic GI conditions provides a snapshot of a highly dynamic ecosystem. In addition to the effects of diet, medication use, lifestyle, and other environmental factors, the variability in microbiome seen over time may also reflect changes in disease activity. We assessed the effect of longitudinal sampling on the identification of compositional changes compared to cross-sectional sampling by subsampling our longitudinal data, testing for significant taxa, and comparing the results at single time points with results obtained on data that were averaged by subject across all time points.

Differences in taxa abundances between HC and disease groups observed in individual time-points were highly inconsistent when comparing the different time points and did not overlap with changes observed in the averaged data (**Figure S1B**). When using averaged data, but not the single-timepoint data, we found a significantly higher abundance of multiple *Streptococcus* spp. individually in IBS-C and IBS-D as well as in the composite IBS group, compared to HC (log2(FC) ~1, at Mann-Whitney *U-*test FDR <0.25) (**Figure S1C, Table S2**). In addition, we found a significantly lower abundance of the recently identified phylum Synergistetes in IBS-D compared to HC (log2(FC) -2.1, FDR 0.017; **Figure S1D, Table S2**). We also found that inter-individual variation dominates over intra-individual variation which supports our approach of averaging the longitudinal data from each individual (**Methods**, t-test p-value <0.0001). These findings highlight the need for longitudinal sampling in chronic diseases to reliably identify microbiota changes that may be missed using cross-sectional sampling. Hence, we primarily report findings from time-averaged data. This is further supported by a recent study showing that commonly used ‘omics’ methods are more accurate when using averages over multiple sampling time points (Poyet et al., 2019).

PCoA-based on Bray-Curtis β diversity showed that stool microbiota composition in IBS clustered by subtype, and IBS-D and IBS-C displayed significantly different dispersion from HC samples as well as from each other (**Figure 1D-E**). To further confirm differences in β diversity, we calculated a Bray-Curtis dissimilarity (BCD)-based irregularity (BCDI) score (**Methods**). BCDI scores for IBS-C were significantly elevated (linear mixed-effect model correcting for subject; **Figure 1F**). When considering a sample to be irregular beyond the 90th percentile of the HC distribution, we found that more IBS-C samples are irregular than IBS-D (31.7% for IBS-C, 14.1% for IBS-D, equality-of-proportions test p-value <0.001).

***Longitudinal sampling reveals greater variability in IBS-C microbiota over time***

Stool microbiota composition exhibited greater variability over time in patients with IBS-C compared to HC and IBS-D subjects (**Figure 1G**). In addition, there was higher Shannon α diversity in averaged IBS-C stool samples compared to IBS-D samples (ANOVA with Tukey HSD p-value 0.016).

We then tested for differences in luminal and mucosa-associated microbiota. These differences are relevant in IBS because disease subtypes, defined by differences in stool form, are partly the result of alteration in epithelial fluid secretion into the lumen. The microbial composition of the colonic mucosa was significantly different from the luminal microbiota in stool samples (**Figure 1H**). The mucosa-associated microbiota in IBS patients were characterized by significantly higher levels of Proteobacteria when compared to HC (**Figure S1G**). The mucosa-associated microbiota in patients with IBS-C were less similar to their respective luminal microbiota than those of IBS-D or HC (**Figure 1I**). This potentially reflects the longer transit time in IBS-C subjects, where there is more time for the communities to diverge. In addition, there was greater intra-individual variability in mucosa-associated microbiota in patients with IBS-C across time, similar to what we observed in the luminal microbiota (**Figure 1J**).

***IBS symptom severity is associated with functional changes in the gut microbiota***

The severity of IBS at a particular sampling point was reported using the IBS symptom severity score (SSS, 0-500), which is a cumulative metric of abdominal pain intensity, frequency, distension, dissatisfaction with bowel habits, and influence of IBS on life in general. We observed a higher relative abundance of more than 20 *Lactobacillus* spp. in severe IBS-D (SSS>300) compared to mild-moderate IBS-D (SSS<300; >10-fold, Mann-Whitney FDR <0.1, **Table S2**). This was not related to probiotic or dairy consumption by the subjects (**Figure S2A-C)**. When considering functional variation through Kyoto Encyclopedia of Genes and Genomes (KEGG) ontology (KO) term abundance in the stool metagenomics data, we found that 74 KO terms were associated with severe IBS-C, and 44 with severe IBS-D at an FDR of <0.1 (**Methods**, **Table S3**). KO terms for alcohol dehydrogenase were found in both severe IBS-C and IBS-D compared to mild-moderate IBS (~0.6 log2(FC) higher in severe IBS). These ADH KO terms are positively correlated to *Bifidobacterium* sp. and *Streptococcus* sp. (**Table S4**). The considerable genetic diversity among ADH enzymes complicates constructing a link between this abundance and specific metabolic products. However, this data suggests that ADH activity may be related to abdominal pain which is the primary symptom common to both IBS-C and IBS-D. In addition, we found that stool form recorded as Bristol stool scale and abdominal pain preceding bowel movements were associated with specific bacteria and metabolites (**Table S4**).

***Metabolomics integrated with physiologic measurements provides mechanistic insight into the effect of gut microbiota metabolism on gastrointestinal function***

To better understand the mechanisms by which the gut microbiota could drive symptom pathophysiology we quantified the metabolic output of the microbiome reflected in the biochemical profiles of the luminal and mucosa-associated samples. We first focused on microbiota-derived metabolites previously reported to drive changes in gastrointestinal physiology.1 H-nuclear magnetic resonance (NMR) spectroscopy showed the short chain fatty acids (SCFA) propionate, butyrate and acetate to be significantly lower in the stool samples of patients with IBS-C compared to HC (**Figure 2A**, **Figure S3A** for averaged data). Consistent with the luminal metabolites, acetate (measured by gas chromatography-mass spectrometry (GC-MS)) was also significantly reduced in the colonic mucosal biopsy samples from the IBS-C group compared to the HC group (**Figure 2B**). Notably, these differences in SCFA were independent of the overall intake of dietary fiber as this was not significantly different between the groups (**Figure S2C**).

We have previously described the role of SCFA in modulating the serotonergic pathway in host GI tissue (Bhattarai et al., 2017b; Reigstad et al., 2015). To determine the physiologic relevance of lower SCFA in stool and biopsies seen in IBS-C patients, we investigated the change in short circuit current (Isc; a measure of ionic flux across the epithelium reflecting intestinal secretion) in colonic epithelium in response to serotonin (5-HT) using an Ussing chamber (**Methods**). Water secretion accompanies ionic flux, and decreased secretion thus results in lower water content of stool as seen in constipation. Conversely, increased ionic flux can result in increased water secretion resulting in diarrhea. The secretory response of colonic biopsies from IBS-C patients to 5-HT was significantly lower than HC (**Figure 2C**) which is consistent with the stool form seen in IBS-C patients.

We recently found that the bacterially-derived monoamine tryptamine (a tryptophan metabolite similar to serotonin) activates serotonin receptor-4 (5-HT4R) resulting in increased fluid secretion and decreased transit time in gnotobiotic mice (Bhattarai et al., 2018), but its physiologic role in human disease has not yet been determined. Hence, we investigated changes in tryptamine and other tryptophan metabolites in stool samples using a targeted liquid chromatography-mass spectrometry (LC-MS) method. We found that both tryptophan and tryptamine were significantly increased in stool samples from IBS-D patients (**Figure 2D**, **Figure S3B**) and could thus in part be responsible for the increased water content of stools in IBS-D. We verified that these metabolite changes were not associated with dietary differences in protein intake (**Figure S2)**.

To establish the capacity of tryptamine to stimulate fluid secretion in human tissue we investigated the tryptamine-induced change in Isc in colonic biopsies from IBS subjects and HC, again using an Ussing chamber. We found that tryptamine significantly increased colonic secretion in all three groups but there were no significant differences among the groups (**Figure S3C**). The lack of such differences indicates that the colonic epithelium of IBS patients and HCs is capable of tryptamine-induced fluid secretion, and observed changes could thus be due to changes in tryptamine abundance.

In humans, the primary bile acids (BA) cholic acid (CA) and chenodeoxycholic acid (CDCA) are deconjugated from their glycine or taurine conjugate by microbial bile salt hydrolases (BSHs). These deconjugated primary BAs then serve as substrates for a diverse range of microbial modifications, including conversion to the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA) and desulfation of DCA-S to DCA. Certain forms of BAs such as hydroxylated bile acids have been found to increase intestinal fluid secretion in humans (Camilleri, 2014). We therefore examined whether there are differences in microbial biotransformation of bile acids in IBS which may contribute to altered intestinal secretion. We identified variation in BA signatures associated with IBS (measured with LC-MS/MS), with significantly higher amounts of unconjugated primary BAs in stool samples from patients with IBS-D and significantly lower amounts of unconjugated primary BAs in stool samples from IBS-C patients (**Figure 2E**) compared to HC. We also found higher amounts of individual primary conjugated and unconjugated bile acids and DCA-S in IBS-D compared to HC and IBS-C subjects (**Figure S3D-F**). As hydroxylated primary bile acids like CDCA may increase colonic secretion, we tested the effect of CDCA in colon mucosa-submucosa preparations from germ-free mice in an Ussing chamber. Indeed, we observed a significant increase in Isc in response to CDCA (**Figure S3G**) which supported a physiological role for the elevated CDCA levels in increasing the water content in stools from IBS-D patients.

To determine the physiologic relevance of differences in tryptamine and primary BA levels, we measured differences in Isc in colonic biopsies obtained from the three groups. As expected from our findings in gnotobiotic mice (Bhattarai et al., 2018), we found colonic biopsies from IBS-D patients also exhibited significantly higher baseline Isc (**Figure 2F**), which is consistent with the secretory effect of tryptamine and primary BA that we have described above.

***Integrated microbiome-metabolome analysis identifies a novel microbial metabolic pathway in IBS***

In addition to the above targeted approach, we employed an untargeted metabolomics approach to identify novel microbial pathways that may be driving pathophysiologic changes in IBS. A projection-to-latent-structures-discriminant-analysis (PLS-DA) model based on untargeted 1H-NMR spectral profiles identified metabolic variation between the IBS subgroups and HC stool samples (**Figure S4A-B**). Lysine, uracil and hypoxanthine were all found to be significantly lower in stool samples from IBS-C patients compared to HC (**Figure 3A-C, Figure S4C-F)**. Hypoxanthine was also lower in IBS-D patients albeit not at the same significance as in IBS-C. Hypoxanthine can serve as an energy source for intestinal epithelial cells and promotes intestinal cellular barrier development and recovery following injury or hypoxia (Lee et al., 2018; Lee et al., 2020). Lower fecal hypoxanthine levels could reflect decreased production or elevated breakdown of hypoxanthine by the microbiome in the gut of IBS patients.

To gain insights into possible microbial contributions to the fecal hypoxanthine pool, we interrogated metagenomics functional modules related to hypoxanthine in stool samples from patients with IBS and HC (**Table S3**). Among the KO terms we found that xanthine dehydrogenase/oxidase (XO; 1.17.1.4) and xanthine phosphoribosyltransferase (XPRT; 2.4.2.22) modules were elevated in IBS-C relative to HC (**Figure 3D)**. XPRT liberates xanthine from xanthosine-monophosphate as an early step in purine salvage. Downstream, XO is an enzyme with low substrate specificity that acts on xanthine or hypoxanthine to produce uric acid. Higher levels of these XPRT and XO modules suggest increased purine breakdown by gut microbiota in IBS patients.

We inspected the metagenomic KO terms **(Table S3)** further to explore two aspects of hypoxanthine metabolism, namely its role in modulating the epithelial energy state,(Lee et al., 2020) and generation of H2O2 and superoxide anions given the putative role of oxidants in IBS (Mete et al., 2013). Four modules from the TCA cycle (L-lactate-, pyruvate-, and formate dehydrogenase, and fumarate hydratase) related to energy metabolism, and 4 terms for alternative forms of respiration (sulfite reductase/ferredoxin, sulfite-, nitrite reductase, and cytochrome-C oxidase) were present at significantly higher abundance in IBS-C stools compared to HC (<q-value 0.1) (**Figure 3D**). Interestingly, the superoxide reductase (1.15.1.2) term was elevated in IBS-C, which could reflect increased capacity to deal with oxidative stress in the IBS-C gut microbiome. This might be necessary in situations of high XO activity. Together this suggests that the microbiome in IBS patients exhibits an increased capacity for hypoxanthine utilization and breakdown, which is congruent with the lower hypoxanthine levels in IBS-C stools.

***Microbial gene-region analysis corroborates associations with bile acid, butyrate and hypoxanthine metabolism***

To further elucidate the microbial contribution to differential metabolite abundances identified in IBS, we first performed direct multivariate correlation analysis based on linear models (Maaslin; <https://huttenhower.sph.harvard.edu/maaslin2>). This identified 60 significant metabolite-species correlations for HC samples, 28 for IBS-C and 46 for IBS-D (**Table S4**). No correlations were present in all groups, 12 were present in HC and IBS-C or IBS-D. Two correlations were present in both IBS-C and IBS-D subgroups (**Table S4**).

While the above correlational approach allows us to identify potential microbial drivers of differences in fecal metabolites, it is unable to identify specific microbial genes that might be relevant for the differences in detected metabolites. We therefore tested for specific bacterial genomic regions that may be responsible for the variation in metabolic output between the groups using the recently described method that associates structurally variable genomic regions to metabolite abundances (SV association) (Zeevi et al., 2019). This analysis allows identification of microbial genes involved in the production or consumption of metabolites by either identifying deletion regions (DRs) that are completely missing from some microbiomes, or variable regions (VRs) which display variable abundance in some microbiomes. We identified 16 DRs and 20 VRs that correlate with 9 and 8 metabolites respectively at a q-value <0.1 (**Table S4**). All DRs were from a single bacterium, *Blautia wexlerae* DSM19850. CDCA was the most frequently associated metabolite, as it covaried with 4 DRs and 7 VRs. This was followed by CA with 3 DRs and 7 VRs. The multitude of associations of microbial genomic regions with bile acids could reflect presently unknown genes that are involved in modification of primary bile acids.

Two regions from *Blautia obeum* ATCC 29174 were present at significantly lower levels in IBS-C samples, and these regions positively correlated with butyrate (**Figure S4G-I**). This is consistent with *Blautia* spp. being butyrate producers and the lower butyrate levels in IBS-C. These regions are 2676-2677 which contains a tetricoat peptide and 2704-2705 which is annotated as a type III ribonuclease.

The strongest observed correlation for the VRs was for a single region from *Lachnospiraceae* sp. 3\_1\_46FAA with hypoxanthine (**Figure 4A-B**). pBLAST analysis (Camacho et al., 2009) perfectly matched the CDS with topoisomerase III (E value = 0). As hypoxanthine is a precursor for energy metabolites and topoisomerase III is linked to DNA replication, this may indicate increased utilization of hypoxanthine for growth. These examples underscore the increased functional resolution that can be achieved using SV association analysis in guiding targeted experiments focused on specific microbial gene regions.

***Microbial metabolism contributes to luminal hypoxanthine levels***

To get more insight into the role of the microbiome in reducing hypoxanthine levels we selected 2 *Lachnospiraceae* strains based on genomic similarity to *Lachnospiraceae* sp. 3\_1\_46FAA identified in the gene-region analysis presented above (**Figure 4A-B)**. We confirmed the presence of the XO gene in these genomes using pBLAST. We included *Hungatella hathewayi* as a positive control as it was highly correlated with the XO KEGG term (**Table S4**, K00087; Spearman rho 0.43, q-value <0.005). All these strains belong to the *Clostridiales* order. *Bifidobacterium longum* ATCC 55813 was included as a negative control since it does not encode XO (as evidenced by pBLAST analysis). We found significant reductions in hypoxanthine levels in the growth medium from the 2 *Lachnospiracea* strains and *H. hathewayi* when compared with *B. longum* using LC-MS (**Figure 4C**).

To determine whether *Lachnospiraceae* also consume hypoxanthine in vivo, we mono-colonized germ-free mice with either *Lachnospiracea* sp.2\_1\_58FAA, or *B. longum* and supplemented hypoxanthine in drinking water (**Figure 4D**). We found significantly lower hypoxanthine levels in cecal contents of mice colonized with *Lachnospiraceae* sp. 2\_1\_58FAA as compared to *B. longum* colonized mice (**Figure 4E**). Since hypoxanthine levels increase upon conventionalization (Matsumoto et al., 2017), this shows that microbially-determined hypoxanthine levels are a consequence of the balance between microbial production and consumption.

***Alteration in gut microbiome and microbial metabolites underlie flares in IBS patients***

IBS is a chronic disease with temporal variability in symptom severity, where most patients will experience transient worsening of symptoms. Our longitudinal analysis above identified a potential link between the gut microbiome and symptom severity in IBS patients. To further confirm that there is a microbial basis for potential exacerbation in symptoms, we examined the additional stool samples collected at the time of self-reported worsening of symptoms (flare) in the subset of patients who provided the additional sample. The flare samples exhibited a higher Bray-Curtis dissimilarity-based irregularity (BCDI) compared to the non-flare baseline combined IBS samples (**Figure 5A-B**), and lower Shannon α-diversity when compared to the averaged samples from the respective IBS subgroup (**Figure 5C**). Specific bacterial taxa were significantly associated with flares, both when considering IBS patients as one group, as well as within IBS-D and IBS-C patients (168 species for combined IBS, 40 for IBS-C, and 7 species for IBS-D at q-value <0.1 from Mann-Whitney test compared to respective averaged baseline samples, **Table S2**). These significant species decreased in abundance almost universally during flare episodes. However, one species of Archaea, *Halobiforma nitratireducens*, was consistently elevated in the flare samples for both subtypes (**Figure 5D)**. This Archaeon is capable of nitrate reduction, an alternative form of respiration that was identified above to be among the energy metabolism-related KO terms that were present at higher abundance in IBS-C.

Primary bile acids were significantly elevated in flare samples of both IBS-C and IBS-D patients (**Figure 5E-F**) inviting speculation on their potential contribution to abdominal pain which is common to both subtypes. We also investigated functional metagenomic KO modules that were associated with flares, with a focus on modules that were previously identified to be associated with symptom severity as well as the newly implicated hypoxanthine metabolic pathway. Of these, an alcohol dehydrogenase and XO module were found at higher abundance in IBS-D flares (log2(FC) 0.78, q-value 0.147, p-value <0.02; XO; log2(FC) 1.36, q-value 0.147, p-value <0.02), which again coincided with increases in TCA and respiration terms identified above (**Table S3**). These observations are also consistent with the findings described above linking IBS symptom severity with the gut microbiome.

The heterogenous nature of IBS suggests there are likely distinct changes that underlie symptoms in individual patients. Hence, we next performed time course analysis of the microbiome in individual patients to identify individual-specific patterns underlying symptom flares. In a patient with IBS-C, time-course permutation analysis revealed an increase in BCDI over time with this trajectory culminating in a flare episode (**Figure S5A**). Several *Streptococcus* spp. were positively correlated with BCDI scores in a subset of subjects (3/6 subjects; **Table S5**). At the functional level, again we found that secretory metabolites including tryptamine, CA and CDCA were elevated in subsets of IBS patients (6/11 for BA and 4/11 for tryptamine) at the time of flare. These observations highlight that unique microbial and metabolic features may underlie worsening symptoms in different patients.

***Microbiome and metabolome data integrated with transcriptomic and epigenetic differences reveal novel host-microbiome interactions in IBS***

As for most chronic conditions, the pathophysiology of IBS is multifactorial with contributions from host pathways, microbial pathways, and host-microbial co-metabolism. To determine the effect of microbial metabolism on host function we first compared transcriptional and epigenetic changes observed in colonic biopsy tissue (**Figure S6, Table S6**). We also used this data to identify putative host-microbial-metabolite interactions in an untargeted way by constructing cross-omics correlation networks that integrate transcriptome data with metabolite and microbiota abundances (**Figure S7, Table S7**).

We identified 82 and 78 differentially expressed (DE) genes when comparing IBS-C and HC or IBS-D and HC (>1 absolute log2(FC) change and p-value <0.05) respectively with 17 genes overlapping in both comparisons (**Figure S6A-D**, **Table S6**). A KEGG pathway enrichment analysis revealed that immune and inflammation-related pathways were enriched in IBS patients (**Figure S6F**). Enriched categories for IBS-C contained genes for prostaglandin D2 synthesis which is involved in regulating smooth muscle contraction (*PTGDS*), B-cell responses to antigen challenges (*CD19* and *CD22*), and antigen presentation via the HLA class II molecule (*HLA-DQA1* and *HLA-DQB1*). Notably, we found no significant changes in any of the pro-inflammatory cytokines that were previously implicated in IBS in either blood or colonic biopsy samples (**Supplementary Mendeley data VI**).

For epigenome analysis we focused on differentially methylated regions (DMRs). We detected 54 DMRs when comparing IBS-C and HC, 75 DMRs when comparing IBS-D vs. HC, and 39 DMRs comparing IBS-C and IBS-D (**Figure S6E**). We next inspected differentially expressed genes that belong to a differentially methylated region (DMR) and identified two genes important for intestinal secretion, *KCNE4* and *AQP1*, which were expressed at lower levels in IBS-D (**Table S6**). KCNE4 is a voltage-gated potassium (Kv) channel that is involved in neuronal excitability, epithelial electrolyte transport, and smooth muscle contraction (Jepps et al., 2009). AQP1 encodes an aquaporin, which are integral membrane proteins that facilitate the transport of water across biological membranes.

KEGG pathway enrichment analysis on the DMR genes showed that the *antigen processing and presentation* pathway was enriched in both IBS subtypes (**Figure S6F, Table S6)**. The same pathway was also enriched in DE genes from IBS-C samples. This enrichment is due to human leukocyte antigen (HLA) class II genes. HLA genes are particularly interesting for IBS as the presence of celiac disease-related *HLA-DQ-2/8* variants were found to be predictive of a favorable response to gluten-free diet in patients with IBS (Vazquez-Roque et al., 2012).

To better understand the implications of the HLA pathway in IBS-C, we inspected the underlying HLA class II genes in more detail and looked for correlations of these genes with the other omics. HLA class II complexes are present on antigen presenting cells (APC) but also on epithelial cells of the gastrointestinal tract and play a central role in the immune system by presenting peptides derived from extracellular proteins. We found a 4-fold higher expression of *HLA-DQA1* and *HLA-DQB1*, which encode the α and β chains from the HLA class II molecule, respectively, in the IBS-C biopsy tissue compared to healthy control biopsies (**Table S6**). In addition, *HLA-DQB1* is preceded by a DMR suggesting that its expression could be due to differential methylation in IBS-C. We found a correlation between *HLA-DQA1* and *Bacteroides vulgatus* in our luminal cross-dataset correlation network (**Figure S7B, Table S7**) inviting speculation on the potential role of (bacterial) antigens in IBS-C.

In addition to the correlation networks highlighted above, we employed a powerful machine learning-based integration approach by applying a Lasso penalized regression model, and used this to identify additional gene-transcript and gene-metabolite associations (**Figure 6, Table S7**). In this network a hub is present around acetate and the *PGLYRP1* and *KIFC3* genes (**Figure 6B**). This could be relevant because acetate is a metabolite that is present at lower abundance both in stool and biopsy samples for IBS-C. *PGLYRP1* is pattern receptor that binds to murein peptidoglycans (PGN) of Gram-positive bacteria and can result in bactericidal activity through interference with peptidoglycan biosynthesis. Indeed, the gene is negatively correlated with the broad family of Gram-positive bacteria *Peptostreptococcaceae*. KIFC3 is a minus-end microtubule-dependent motor protein required for zonula adherens maintenance and thus implicated in barrier function. This illustrates that the use of various omics integration approaches generates a wealth of hypotheses that can be used to contextualize the observed changes across omics data layers (**Figure 6**, **Figure S7**, **Table S7**).

***Multi-omics integration identifies purine starvation in colonic epithelium as a potential novel mechanism underlying IBS***

Above we identified significantly lower fecal hypoxanthine abundance in IBS-C and IBS-D, established that microbial hypoxanthine degradation leads to lower intestinal hypoxanthine levels, and identified functional changes that point to increased purine degradation by the microbiome in IBS-C stools (**Figure 3**, **Figure 7**). However, since hypoxanthine is a host-microbial co-metabolite, its pool can be affected by both microbial and host metabolism. To determine the host response to the reduced hypoxanthine pool, we examined changes in purine metabolism gene expression in colonic biopsies. Gene expression of human xanthine oxidase (encoded by the *XDH* gene) was elevated in colonic biopsies of both IBS subtypes when compared to HC and this was consistent in both time points with a log2 (FC) ranging between 0.26 and 0.65 (**Figure 7B, Table S6**). This suggests that depletion of the hypoxanthine pool may be the result of increased XO activity from both the microbiome and the host.

Intestinal epithelial cells have limited capacity for de novo synthesis of purines and instead predominantly rely on salvage pathways for adenylate biosynthesis (**Figure 7C**) (Biaggioni et al., 2015; Grimble, 1994). Hence, to identify secondary effects in the host resulting from depletion of the hypoxanthine pool, we inspected possible transcriptional changes in the purine salvage pathway. Purine nucleoside phosphorylase (*PNP*), the first gene in the purine salvage pathway, was expressed ~2 fold higher in both IBS-C and IBS-D (**Figure 7A**, **Table S6**), and within IBS patients *PNP* expression displayed a negative correlation with hypoxanthine levels (**Figure 7D**). Importantly, variation in host genetics is not responsible for these differences in gene expression as Illumina global screening arrays revealed that single nucleotide polymorphisms (SNPs) in *XDH* and *PNP* were not differentially distributed between IBS subgroups and healthy controls. Together, these findings suggest a model where elevated degradation of purine nucleotides by the microbiota and the host induces metabolic stress in colonic tissue. In turn, this may lead to a compensatory response by increasing purine salvage. Using this multi-omics view we suggests that low levels of purine nucleotides may result in lower epithelial energy state and capacity for mucosal repair which may in part underlie the pathophysiology of IBS.

**Discussion**

In this study we describe findings from an integrated longitudinal multi-omics analysis of the gut microbiome, metabolome, host epigenome and transcriptome in the context of host physiology in patients with different subtypes of IBS. Several multi-omics integration tools enhanced our ability to focus on a specific set of pathways with potential biological significance in IBS.

Baseline colonic secretion was increased in IBS-D patient biopsies which would suggest either an inherent change in epithelial transport or an increase in metabolites that promote fluid secretion. The observed increases in secretagogues such as the primary bile acid CDCA acid and bacterial metabolite tryptamine suggests that higher levels of microbiota-related secretory compounds likely drives increased secretion in IBS-D. This is further supported by the lack of significant differences in secretory response to tryptamine among colonic biopsies from the three groups, which would be expected if there were inherent defects in the colonic epithelium.

Previous studies have suggested that bile acid malabsorption drives increased intestinal secretion in IBS-D, but the lack of a concurrent increase in secondary BA along with primary BAs in our study, suggests decreased microbial biotransformation of primary BA may at least in part be driving this effect.

Through further targeted integration of multiple host and microbiome data layers we identified the host-microbial pathway of purine metabolism which may play an important role in the pathophysiology of IBS. This is the first time that hypoxanthine has been implicated in IBS pathogenesis, including prior gnotobiotic studies on animal models. This illustrates the relevance of employing multi-omics measurements in humans to identify potential disease mechanisms that may depend on human-specific responses in gene expression. Hypoxanthine is an appealing drug target given the availability of the xanthine oxidase inhibitor allopurinol which is used to treat gout (Becker et al., 2009), and thiopurines which are used to optimize inflammatory bowel disease therapy (Moreau et al., 2017). There are also multiple drugs in development with more specific activity against xanthine oxidase which may be relevant in the future.

Our study provides multiple new therapeutic targets for future investigation. The apparent decreased microbial biotransformation of BA in IBS-D patients may be treated using defined microbial consortia with a high capacity of conversion of chenodeoxycholic acid to lithocholic acid. Similarly, in IBS-C patients, increased production of bacterial SCFA and/or tryptamine may be viable therapeutic strategies. Finally, stimulating microbial hypoxanthine production or inhibition of xanthine oxidase locally in the gut would be a novel approach to increase the amount of luminal hypoxanthine without systemic effects and may be beneficial in IBS independent of disease subtype. Another interesting focus is the reported effect of liver bile acid signaling on XO activity, as it is unclear if this relationship also exists in the digestive tract (Kanemitsu et al., 2017).

In summary, our integrated longitudinal multi-omics study highlights how we can leverage human studies to advance our understanding of diseases with both host and microbial components to identify targets for improved treatment.

**Limitations**

We acknowledge that our study has some limitations. We realize that our findings are not a proof of causation even though we primarily focused on biologically plausible mechanisms. In order to increase rigor and confidence in our findings, we integrated multiple data types and primarily reported pathways that were identified across different datatypes. We focused primarily on the colonic microbiome but we are aware that the small intestine likely plays an important role in generation of IBS symptoms (Saffouri et al., 2019). Longitudinal studies dedicated to the small intestinal microbiome are needed to complement our findings and advance our understanding of IBS. In addition, longitudinal multi-omics data like presented in this study could help in moving away from phenotype-based to mechanism-based IBS subtyping.

**Acknowledgments**

The authors like to thank Lyndsay Busby for secretarial assistance. This work was supported by NIH grant DK114007 (P.C.K.), the Center for Individualized Medicine, Mayo Clinic, Rochester, MN (P.C.K.); the Minnesota Partnership for Biotechnology and Medical Genomics (P.C.K. and D.K.); the STRATiGRAD PhD training program of Imperial College London (<https://www.imperial.ac.uk/stratigrad/>) (Y.Y.); Société des Produits Nestle (J.R.S.); Imperial College NIHR BRC (J.R.S.); and NIH grant R35-GM128716 (R.B.).

**Author Contributions**

D.K and P.C.K. designed the experiments and the overall data analysis. R.A.T.M., D.K and P.C.K. wrote the manuscript with input from co-authors. H.R.L., Y.B. and P.C.K. coordinated human subject recruiting and sampling. Y.Y., T.W. and H.R.L. contributed to sample processing data generation and analysis. T.W., X.T., Z.S., T.Z., W.vT., S.H., A.C., Y.Y. and R.A.T.M. analyzed data. S.P., X.T., K.R.K., T.K., M.H., N.B., W.vT., S.H., R.B., Y.Y. and R.A.T.M. performed data integration. T.O., M.G., M.D., M.C., E.E., E.S., R.B., G.Fa., G.Fr., J.So., J.Sw., D.K., K.R.K. and P.C.K directed research and provided critical feedback. T.O., M.G., G.Fa., M.C. and P.C.K. performed clinical data analysis. Y.B. and P.C.K. contributed to design and execution of Ussing chamber experiments.

**Declaration of Interests**

P.C.K.: Advisory Board of Novome Biotechnologies, ad hoc consultant for Pendulum Therapeutics, IP group inc., and Otsuka Pharmaceuticals. P.C.K. holds patent US20170042860A1 for use of tryptamine producing bacteria (“Methods and materials for using *Ruminococcus gnavus* or *Clostridium sporogenes* to treat gastrointestinal disorders”) and P.C.K. and Mayo Clinic have a financial interest related to this research. These interests have been reviewed and managed in accordance with Mayo Clinic Conflict-of-Interest policies.

D.B.K.: D.B.K. serves as CEO of CoreBiome, a company involved in the commercialization of microbiome analysis and a wholly owned subsidiary of OraSure Technologies. These interests have been reviewed and managed by the University of Minnesota in accordance with its Conflict-of-Interest policies.

**Main Figure Titles and Legends**

**Figure 1. Gut microbiota composition of IBS-C patients is more distinct and variable**

1. Outline of sample collection.
2. Number of subjects and distribution of biological sex by cohort.
3. Total number of samples per subject collected longitudinally.
4. Bray Curtis β-diversity ordination of samples from IBS-C, IBS-D, and HC considering all samples from all subjects (n=474 stool samples, no. of samples per subject 1-7).
5. Same as D considering by-subject averaged data (statistics in inset from PERMANOVA on group membership). IBS-C and IBS-D vs. HC, p-value <0.05, IBS-C vs IBS-D, p-value 0.001, dispersion around centroids via pairwise PERMANOVA (n=22, 29, 24 averaged gut microbiome profiles for IBS-C, IBS-D, and HC, respectively).
6. Bray-Curtis dissimilarity (BCD)-based irregularity (BCDI) showing distribution of the three groups linear mixed-effect model correcting for subject HC vs. IBS-C p-value <0.011 (n=142, 170, 143 stool samples for IBS-C, IBS-D, and HC, respectively).
7. Community variability determined by the mean within-subject Bray Curtis distance (within-IBS-D vs. within-IBS-C, p-value <0.005, ANOVA Tukey, n=22, 46, 24, 53, 29, Bray-Curtis distances between stool samples of the same subject for within-IBS-C, Healthy vs. IBS-C, within-Healthy, Healthy vs. IBS-D, and within-IBS-D, respectively).
8. Bray Curtis β-diversity ordination of biopsy and stool samples (statistics in inset from PERMANOVA on group membership. n=72, 12, 462 stool samples for biopsy, flare, stool, respectively).
9. Difference in mucosa associated and luminal microbiota composition based on Bray-Curtis distance (HC vs IBS-C, IBS-D vs IBS-C p-values <0.001, ANOVA Tukey HSD; n=20, 22, 19 paired mucosal-stool microbiome samples for IBS-C, IBS-D, and HC, respectively).
10. Community variability within each group based on mean Bray Curtis Distance (HC vs IBS-C, p-value 0.02, ANOVA Tukey HSD, n=10, 11, 9 mucosal microbiome samples for IBS-C, IBS-D, and HC, respectively).

Boxplot center represents median and box interquartile range (IQR). Whiskers extend to most extreme data point <1.5 x IQR. C: IBS-C, D: IBS-D, H: HC. Symbols indicate significance (\* <0.05).

**Figure 2. Metabolomics integrated with physiologic measurements provides mechanistic insight into the effect of gut microbiota metabolism on gastrointestinal function**

1. Relative abundance of propionate, butyrate, and acetate in stool samples determined with 1H NMR (linear mixed-effect models on log10-transformed data correcting for subject, FDR corrected, n=136, 170, 146 metabolite profiles for IBS-C, IBS-D, and HC, respectively).
2. Absolute abundance of acetate in colonic biopsies determined with GC-MS (linear mixed-effect models on log10-transformed abundance correcting for subject, FDR corrected, n=28, 23, 23 averaged metabolomes for IBS-C, IBS-D, and HC, respectively).
3. Maximal ΔIsc (Imax) following application of increasing concentrations of serotonin (5-HT) basolaterally in colonic biopsies from time-point 1 (ANOVA Tukey HSD, n=13, 12, 10 colonic biopsies for IBS-C, IBS-D, and HC, respectively).
4. Absolute abundance of tryptophan and tryptamine in a subset of the stool samples determined with LC-MS/MS (ng/mg stool) (linear mixed-effect models on log10-transformed data correcting for subject, FDR adjusted, n=84, 91, 103 metabolite profiles for IBS-C, IBS-D, and HC, respectively).
5. Relative abundance of primary unconjugated bile acids in stool samples determined with LC-MS/MS. Data shown is the sum of cholic acid and chenodeoxycholic acid relative abundances (linear mixed-effect models on log10-transformed data correcting for subject, n=136, 170, 146 metabolite profiles for IBS-C, IBS-D, and HC, respectively)
6. Baseline Isc (ANOVA Tukey HSD, n=16, 12, 13 colonic biopsies for IBS-C, IBS-D, and HC, respectively).

Boxplot center represents median and box interquartile range (IQR). Whiskers extend to most extreme data point <1.5 x IQR. Symbols indicate significance (\*\*\* <0.001, \*\* <0.01, \* <0.05, ^ <0.10).

**Figure 3. Integrated microbiome-metabolome analysis identifies a novel microbial metabolic pathway in IBS.**

(A-C) Relative abundance of (A) lysine, (B) uracil and (C) hypoxanthine in stool samples determined with 1H NMR (linear mixed-effect models on log10-transformed data correcting for subject, FDR adjusted, n=136, 170, 146 metabolite profiles for IBS-C, IBS-D, and HC, respectively). Boxplot center represents median and box interquartile range (IQR). Whiskers extend to most extreme data point <1.5 x IQR. Symbols indicate significance (\*\*\* <0.001, \*\* <0.01, \* <0.05).

(D) Selected hypoxanthine-related gut metagenome KO term abundance in stools from IBS-C subjects compared to the median abundance of the healthy control subjects (HC). By-subject averaged data (FDR <0.1, Mann-Whitney test; except for K00769 which had q-value 0.12). The maximal log2(fold-change) of the either of the xanthine dehydrogenase/oxidase modules is 0.73, p-value <0.005, q-value 0.09 for IBS-C, and log2(FC) 0.49, p-value <0.07 for IBS-D. Error bars show SD and middle line indicates median (IBS-C n=22 averaged microbiome compositions). All KO term associations can be found in **Table S3**.

**Figure 4. Hypoxanthine consumption by specific gut microbiome members as suggested by microbial gene region associations.**

1. Scatter plot of metabolite intensities and standardized region coverage for SV association result for *Lachnospiraceae* sp. 3\_1\_46FAA genomic region positively correlated to hypoxanthine (Spearman correlation inset, n=13, 13, 5 averaged microbiome abundances with *Lachnospiraceae* bacterium 3-146FAA present above threshold for IBS-C, IBS-D, and HC, respectively).
2. Genomic context of region from A with relevant gene highlighted in red.
3. 3 *Clostridiales* strains and *B. longum* were grown in Mega medium. Hypoxanthine levels in the culture supernatant after ON growth were determined with LC-MS (ANOVA Tukey HSD on log2(fold change), n=3 cultures per strain).
4. Outline of monocolonization mouse experiment verifying in vivo hypoxanthine consumption. 3 female GF Swiss Webster mice were oral gavaged with ~2\*106 CFU of either *B. longum* or *Lachnospiraceae* sp. 2\_1\_58FAA and co-housed for the duration of the experiment. Hypoxanthine was supplied in drinking water to mimic exogenous production by the microbiome. On day 4 after gavage mice were sacrificed and cecal contents were collected.
5. Hypoxanthine and xanthine pool size was determined in cecal contents using enzyme assays. Samples were corrected for baseline levels of H2O2 in the sample based on parallel reactions without XO enzyme (Welch t-test on averaged duplicate samples, n=3 cecal contents from 3 mice per colonization status).

Error bars indicate standard error of the mean (sem). Symbols indicate significance (\*\* <0.01, \* <0.05).

**Figure 5. Alteration in gut microbiome and microbial metabolites underlie flares in IBS patients.**

1. Bray-Curtis dissimilarity (BCD)-based irregularity (BCDI) showing distribution of IBS flare and all non-flare IBS samples (linear mixed-effect model correcting for subject, IBS non-flare vs. IBS flare p-value <0.01, n=312, 12 gut microbiome profiles for IBS non-flare, IBS flare, respectively).
2. Within-disease comparisons of BCDI score (p-values from linear mixed-effect model correcting for subject, n=142, 6, 170, 6 gut microbiome profiles for IBS-C non-flare, IBS-C flare, IBS-D non-flare, and IBS-D flare, respectively).
3. Within-disease comparisons of α-diversity in flare samples compared to by-subject averaged baseline data (Shannon diversity at species level, p-values from Mann-Whitney *U*-test, n=22, 6, 29, 6 averaged gut microbiome profiles for IBS-C non-flare, IBS-C flare, IBS-D non-flare, and IBS-D flare, respectively).
4. Relative abundance of *Halobiforma nitratireducens* in flare and non-flare IBS samples (q-value <0.001, Mann-Whitney *U*-test, n=51, 12 averaged gut microbiome profiles for IBS non-flare, IBS flare, respectively).
5. Relative abundance of bile acids cholic acid in stool samples determined with LC-MS/MS (linear mixed-effect models on log10-transformed data correcting for subject, FDR adjusted, n=136, 6, 170, 6 metabolite profiles for IBS-C non-flare, IBS-C flare, IBS-D non-flare, and IBS-D flare, respectively).
6. Same as in E for chenodeoxycholic acid.

Boxplot center represents median and box interquartile range (IQR). Whiskers extend to most extreme data point <1.5 x IQR. C: IBS-C, D: IBS-D, H: HC. Symbols indicate significance (\*\*\* <0.001, \*\* <0.01, \* <0.05).

**Figure 6. Multi-omics integration results from Lasso penalized regression**

1. Network representing significant and stability-selected correlations of host genes (grey nodes) with fecal microbial taxa (blue nodes) and fecal metabolites (yellow nodes) at FDR < 0.25. Purple edges indicate positive correlation and red edges indicate negative correlation, edge width indicates the strength of correlation (Lasso regression using 25 IBS patients and 13 matched healthy control datasets).
2. Lasso correlation plots between acetate with PGLYPR1 (FDR <0.001) and acetate (FDR <0.05) from network shown in A). Orange and blue points represent IBS-C and IBS-D subjects, respectively.
3. Same as B for KIFC3.

**Figure 7. An integrated multi-omics view of IBS points to microbiome-host interactions in the purine salvage pathway**

1. Purine nucleoside phosphorylase (PNP) expression in colonic biopsy tissue (For A and B; ANOVA Tukey HSD, n=15, 8, 8 time-point averaged female biopsy transcriptomes for IBS-C, IBS-D, and HC, respectively). For full statistical results split by time point see **Table S6** (p-value <0.001 for IBS-C and IBS-D vs HC for biopsies from first time point (IBS-D vs. HC FDR 0.018), from generalized binomial test).
2. Gene expression of human xanthine dehydrogenase (XDH) in colonic biopsy tissue. For full statistical results split by time point see **Table S6** (p-value 0.022 for IBS-C and 0.101 for IBS-D in time point 1, and <0.005 for time point 2 (with IBS-C vs. HC FDR <0.05), from generalized binomial test).
3. Simplified human-microbiome purine nucleotides degradation pathway with identified IBS-relevant changes indicated. Black arrows indicate metabolic steps, yellow and blue up arrows indicate elevated expression or abundance in IBS.
4. Lasso correlation plot between hypoxanthine and PNP (FDR <0.001). Orange and blue points represent IBS-C and IBS-D subjects, respectively.
5. Metagenomic xanthine oxidase module abundance for all groups (also shown in Figure 3D for IBS-C; IBS-C vs HC FDR <0.1, Mann-Whitney *U*-test. n=22, 29, 24 averaged gut microbiome profiles for IBS-C, IBS-D, and HC, respectively).

Boxplot center represents median and box interquartile range (IQR). Whiskers extend to most extreme data point <1.5 x IQR. Symbols indicate significance (\* <0.05, ^ <0.1, ^^ <0.2).

**Supplementary Figure Titles and Legends**

**Figure S1. Related to Figure 1. Longitudinal sampling overcomes heterogeneity seen across cross-sectional microbiome studies**

1. Cohort description. Age in years.
2. Dotplot of the number of taxa and metabolites identified at FDR <0.25 for the comparisons in the 3 panels (Two-sided Mann-Whitney *U*-test). For the metagenomics panels on the left selected groups of taxa names are listed to illustrate that there is no overlap between taxa that are identified in data from one of the time points (0-6) and the collapsed data. Colors indicate different taxonomic levels. For the metabolomics panel on the right names for all metabolites that met the threshold are indicated. There is a higher level of cross-sectional consistency in the metabolome compared to the microbiome (for n numbers see **Table S1**).
3. Representative plots displaying the relative abundance of 4 *Streptococcus* sp. that are found at significantly higher abundances in IBS compared to HC (n=51, 24 averaged gut microbiome profiles for IBS and HC, respectively). Two-sided Mann-Whitney *U*-test FDR <0.25 (results from all comparisons can be found in **Table S2**).
4. Representative plots displaying the relative abundance of 2 phyla that are significantly depleted in IBS-D compared to HC (n=29, 24 averaged gut microbiome profiles for IBS-D and HC, respectively). Two-sided Mann-Whitney *U*-test FDR <0.25.
5. Representative plots displaying the relative abundance of 2 species that are significantly elevated in IBS-C compared to HC (n=22, 24 averaged gut microbiome profiles for IBS-C and HC, respectively). Two-sided Mann-Whitney *U*-test FDR <0.25.
6. Representative plots displaying the relative abundance of 2 bacterial families that are found at significantly higher abundances in IBS compared to HC (n=51, 24 averaged gut microbiome profiles for IBS and HC, respectively). Two-sided Mann-Whitney *U*-test FDR <0.25
7. Representative plots showing abundance of Proteobacteria in colonic biopsies obtained from IBS-C and HC at two different time points (T1; n=29, 13 and T2; n=21, 9 averaged gut microbiome profiles for IBS and HC, respectively). Two-sided Mann-Whitney *U*-test FDR <0.25.

Boxplot center represents median and box interquartile range (IQR). Whiskers extend to most extreme data point <1.5 x IQR.

**Figure S2. Related to Figure 1. No differences in dietary intake between cohorts.**

(A) Average food intake from 24-hour recalls was assessed using tree-based food diversity analysis. Dietary diversity was not different between cohorts (PERMANOVA, p = 0.21, 999 permutations).

(B) Dietary intake data from 24-hour recalls shared similarities with baseline food frequency questionnaires (FFQ) and 24-hour recall food groups were correlated with FFQ measured Healthy Eating Index (HEI) scores and variables (Spearman correlation, \* indicates FDR corrected p-value < 0.25).

(C) FFQ measured HEI Scores, fiber intake, and protein intake were not different between cohorts.

**Figure S3. Related to Figure 2. Averaged metabolomics data and additional physiologic measurements.**

1. Relative abundance of propionate, butyrate, and acetate in stool samples determined with 1H NMR (averaged data per subject, FDR adjusted pairwise Mann-Whitney tests, n=23, 29, 24 averaged metabolomes for IBS-C, IBS-D, and HC, respectively).
2. Absolute abundance of tryptophan and tryptamine in a subset of the stool samples determined with LC-MS/MS (ng/mg stool) (averaged data per subject, FDR adjusted pairwise Two-sided Mann-Whitney *U*-test, n=23, 29, 24 averaged metabolomes for IBS-C, IBS-D, and HC, respectively).
3. Maximal ΔIsc (Imax) following application of increasing concentrations of tryptamine basolaterally in colonic biopsies from time-point 1 (no significant difference ANOVA Tukey, n=13, 12, 10 colonic biopsies for IBS-C, IBS-D, and HC, respectively).
4. Relative abundance of bile acids cholic acid, chenodeoxycholic acid, and deoxycholic acid sulphate in stool samples determined with LC-MS/MS (linear mixed-effect models on log10-transformed data correcting for subject, FDR adjusted, n=136, 170, 146 metabolite profiles for IBS-C, IBS-D, and HC, respectively).
5. Relative abundance of bile acids cholic acid, chenodeoxycholic acid, and deoxycholic acid sulphate in stool samples determined with LC-MS/MS (averaged data per subject, FDR adjusted pairwise Two-sided Mann-Whitney *U*-test, n=23, 29, 24 averaged metabolomes for IBS-C, IBS-D, and HC, respectively).
6. Relative abundance of bile acids glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, and taurochenodeoxycholic acid in stool samples determined with LC-MS/MS (linear mixed-effect models on log10-transformed data correcting for subject, FDR adjusted, n=136, 170, 146 metabolite profiles for IBS-C, IBS-D, and HC, respectively).
7. ΔIsc (Imax) following application CDCA basolaterally in proximal colon mucosa submucosa preparations from germ free mice (n=3 mice, Wilcoxon signed rank test, error bars indicate SE).

Boxplot center represents median and box interquartile range (IQR). Whiskers extend to most extreme data point <1.5 x IQR. Symbols indicate significance (\*\*\* <0.001, \*\* <0.01, \* <0.05, ^ <0.1, ^^ <0.2).

**Figure S4. Related to Figure 3 and 4. Averaged and additional metabolomics and integration data.**

1. Projection-to-latent-structures-discriminant-analysis (PLS-DA) results shown for the 3.8 - 8.5 ppm range of the 600 MHz 1H NMR spectrum for IBS-C stool samples compared to healthy control samples. Top panels display the averaged spectra with blue features representing features that the model identifies to have a lower relative abundance in IBS-C compare to HC. Bottom panel shows the corresponding Manhattan plot for all 30611 spectral variables in the OPLS-DA model. Variables in red indicate higher relative abundance. However, these variables correspond to noise and have no metabolite feature assigned. PLS-DA model characteristics were R2Y = 0.28, Q2Y = 0.15, RCV = 0.88 (n=136, 146 metabolite profiles for IBS-C and HC, respectively)
2. Same as panel A for spectral range of 0 -3.8 ppm
3. Relative abundance of lysine in stool samples determined with 1H NMR (FDR adjusted pairwise Two-sided Mann-Whitney *U*-test, (n=23, 29, 24 averaged metabolomes for IBS-C, IBS-D, and HC, respectively).
4. Relative abundance of uracil in stool samples determined with 1H NMR.
5. Relative abundance of hypoxanthine in stool samples determined with 1H NMR.
6. Time course analysis using santaR for hypoxanthine showing hypoxanthine is consistently lower in IBS-C and IBS-C. The analysis is based on 1,000 bootstrap rounds (95% confidence interval), 1,000 permutation rounds and 4 degrees of freedom.
7. Scatter plot of metabolite intensities and standardized region coverage for SV association result for *Blautia obeum* ATCC 29 genomic regions positively correlated to butyrate (Spearman correlation inset, n=11, 6, 8 averaged microbiome abundances with *Blautia obeum* ATCC 29 present above threshold for IBS-C, IBS-D, and HC, respectively).
8. Mann-Whitney *U*-test comparison of genomic region abundance from G across cohorts.
9. Genomic context of region from G with relevant gene highlighted in red.

Boxplot center represents median and box interquartile range (IQR). Whiskers extend to most extreme data point <1.5 x IQR. Symbols indicate significance (\*\*\* <0.001, \*\* <0.01, \* <0.05, ^ <0.1, ^^ <0.2).

**Figure S5. Related to Figure 5. Alteration in gut microbiome and microbial metabolites underlie flares in IBS patients.**

(A-M) The same 6 features are plotted for 13 subjects in panels A-M. The most left plot (1st column) represents the Bray-Curtis dissimilarity (BCD)-based irregularity for microbiome stool samples. Significant time-dependent patterns are indicated with a p-value (p-value from sum of squares of 3rd order polynomial fits from 99 perturbations). Black line is a 3rd order polynomial spline fit. Grey lines indicate median and 90th percentile of median HC dissimilarities, green dots indicate a flare. For the other plots the personalized Z-scores of the indicated metabolites (2nd – 4th column) and KEGG modules (5th and 6th column) are plotted. In these plots grey horizontal lines indicate the Z-score at 0 and at alpha level of 0.05 (|Z| = 1.645). Green dots again indicate flare samples.

**Figure S6. Related to Figure 7. Epigenetic and transcriptomic changes in colonic biopsies as a measure of host physiologic state in IBS.**

1. Volcano plot of differentially expressed (DE) genes when comparing HC and IBS-C from T1 samples. Genes with absolute log2 fold change ≥1 and nominal p-value <0.05 are colored in red (generalized binomial test from edgeR, n=14, 6, 8 time point 1 biopsy transcriptomes from female IBS-C, IBS-D, and HC subjects, respectively).
2. Same as in A for HC and IBS-D comparison.
3. Same as in A for the IBS-C and IBS-D comparison.
4. Venn diagram displaying the number of genes that overlap between significantly DE genes from HC vs IBS-C comparison (HvC), HC vs IBS-D comparison (HvD), and IBS-C and IBS-D comparison (CvD).
5. Venn diagram displaying the number of genes that overlap between significant differentially methylated regions (DMR) from HC vs IBS-C comparison (HvC), HC vs IBS-D comparison (HvD), and IBS-C and IBS-D comparison (CvD) (Clusters of differentially methylated CpGs (p-value <0.01 and > 5% difference in methylation) identified with bumphunter algorithm defined as a minimum of 4 probes in the region with adjusted DMR p-value <0.05 through permutation test, n=14, 6, 8 time point 1 biopsy methylome profiles from female IBS-C, IBS-D, and HC subjects, respectively).
6. KEGG pathway enrichment results for significant DE and DMR genes (see above for definitions of DE and DMR; p-value <0.05 from RITAN KEGG enrichment).

**Figure S7. Related to Figure 6. Data integration using correlation networks.**

1. Biopsy Spearman correlation network containing time point 1 host transcriptome, biopsy metabolome and biopsy microbiome.
2. Luminal Spearman correlation network containing collapsed host transcriptome, luminal metabolome and luminal microbiome.

**STAR Methods text**

**RESOURCE AVAILABILITY**

**Lead Contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Purna Kashyap, MBBS (kashyap.purna@mayo.edu).

**Materials Availability**

This study did not generate new unique reagents.

**Data and Code Availability**

Processed data for metagenomics, metabolomics, and cytokine measurements is available as a Mendeley dataset (doi:10.17632/29n2z5r5ph.4). RNAseq and methylome data was deposited at the Gene Expression Omnibus (GEO) (GSE146853). Microbiome sequencing reads are deposited at the European Nucleotide Archive (ENA) (PRJEB37924). Raw data from metabolomics measurements are deposited at the MetaboLights repository (MTBLS1396). Code used for metagenome and metabolome data analysis is available at https://gitlab.com/rubenmars/ibs-multi-omics-code.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Recruitment and exclusion criteria**

Mayo Clinic Rochester was the only medical center participating in the study. Participants were recruited through Mayo Clinic Institutional Review Board (IRB)-approved advertisements (newspaper advertisement, Mayo Clinic classifieds, “Volunteers Sought” flyers posted on campus, pamphlets given to IBS patients, letters mailed to home, word of mouth, clinicaltrials.gov, and Mayo research website). Healthy subjects and IBS-C and IBS-D patients between 18-65 years old who expressed interest were invited to undergo screening to assess eligibility. Participants were given the option of undergoing two flexible sigmoidoscopies. All IBS-C and IBS-D subjects fulfilled Rome III criteria. Recruitment of healthy subjects was matched with IBS subjects for age, sex and BMI.

Volunteers with prior history of abdominal surgeries (except appendectomy and cholecystectomy), diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease, or other inflammatory conditions, antibiotic use within the past 4 weeks, bleeding risk or taking medication that increases bleeding risk (only for those who chose to undergo the flexible sigmoidoscopies), bowel prep for colonoscopy in the past week, pregnancy, plan to become pregnant during study, being a vulnerable adult, and age below 18 or over 65 were excluded. In addition, people were excluded with other diseases, conditions, or habits that would interfere with study completion, increased risks with flexible sigmoidoscopies (if chosen), or that in judgment of the investigator would potentially interfere with compliance to study or adversely affect outcomes.

**Regulatory compliance**

The study was approved and reviewed yearly through the IRB of Mayo Clinic Rochester. All participants provided written informed consent before any study-related activities were completed.

**Participant and sample metadata**

Additional info on study subjects was collected at the first visit after study consent for IBS and healthy volunteers. This included recording of medical history and a limited exam by the study physician where height, weight, BMI and vital signs were noted. Furthermore, study subjects underwent a dietitian consult where explanation on Food Frequency Questionnaires (FFQ) and 24-hour dietary recall questionnaire training was given. Additional questionnaires at the first visit were Rome III criteria for IBS diagnosis, IBS symptom severity (also completed monthly for IBS participants), microbiome health, bowel disease questionnaire (BDQ-6), Hospital Anxiety and Depression, IBS Quality of Life, and a 7-day Bowel Diary (also completed monthly for all participants).

**Animal experiments**

Mouse experiments were performed on female mice born and maintained in the Mayo Clinic Germ-Free Mouse Facility as previously described (Reigstad et al., 2015). Experiments complied with Institutional Animal Care and Use Committee guidelines (IACUC protocol no. A00003920-18).

**METHOD DETAILS**

**Specimen collection and data generation**

Stool specimens were completed via home collection kits at the earliest convenience after the initial visit and then monthly for six months. Sample tubes were returned on frozen gel packs overnight using FedEx or dropped off at the clinical core facility of Mayo Clinic Center for Cell Signaling where samples were stored at -80°C.

Blood samples (plasma, serum, whole blood) were collected at the initial visit only and stored at -80˚C upon further processing.

Biopsies were obtained through flexible sigmoidoscopy from the sigmoid colon 20-30 cm from the anal verge essentially as described previously (Bhattarai et al., 2018; Peters et al., 2017). Up to two tap water enemas were given to cleanse colon for each procedure. All endoscopic procedures were performed by a single endoscopist (P.C.K.) and up to twelve colonic biopsies were collected using a large-capacity (2.8 mm) biopsy forceps without pin. Depending on downstream processing the biopsies were placed in RNAlater stabilization solution (Invitrogen), directly frozen in liquid nitrogen, or placed in glucose Krebs solution on ice (composition in mM: 11.5 D-glucose, 120.3 NaCl, 15.5 NaHCO3, 5.9 KCl, 1.2 NaH2PO4, 2.5 CaCl2.2H2O, and 1.2 MgCl2; pH 7.3–7.4) and immediately transported to the laboratory for experiments.

**Ussing chamber experiments**

Colonic mucosal secretory responses were assessed using Ussing chamber setups. Biopsies were mounted within 45 min of collection in 4 ml Ussing chambers (Physiologic instruments, San Diego, USA) with an aperture of 0.31 cm2. The basolateral side of the chamber was bathed with 4 mL of glucose Krebs solution while the apical side was bathed with 4 mL of Krebs Mannitol solution (composition in mM: 11.5 D-mannitol, 120.3 NaCl, 15.5 NaHCO3, 5.9 KCl, 1.2 NaH2PO4, 2.5 CaCl2.2H2O, and 1.2 MgCl2; pH 7.3–7.4). The chamber was bubbled with a 97% O2 and 3% CO2 gas mixture. Tissue viability was confirmed by using concentration response measurements to acetylcholine (1 mM–3 mM) added on the submucosal side prior to the start of experiments. Short circuit current (Isc) was continuously recorded using Acquire and Analyze software (Physiologic instruments, San Diego, USA). ΔIsc values were calculated using Isc measurements before and after application of compounds to the basolateral side and normalized to the tissue area. Tryptamine and serotonin were added at 11 cumulatively increasing concentrations from 0.003 μM to 300 μM. Imax is the maximal Isc value achieved at any of the concentrations.

**Microbiome DNA sequencing and alignment**

DNA extraction and sequencing was performed at the University of Minnesota Genomics Center (UMGC). DNA was extracted from stool and biopsy sections using the Qiagen PowerSoil kit (Qiagen, Germantown, MD, USA) and was quantified using a NanoDrop-8000 UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and PicoGreen assays. Shotgun metagenomic sequencing library preparation for stool samples was completed using a modified NexteraXT protocol followed by sequencing on a HiSeq 2500 (Rapid Mode) with 100 bp single-end reads (1x100) or on a NextSeq with 150 bp single-end reads (1x150). To minimize sequencing batch effects samples from the three cohorts were assigned randomly to two sequencing runs. Shotgun reads were trimmed to a maximum of 100 bp prior to alignment. Shotgun sequences were aligned to the RefSeq representative prokaryotic genome collection (release 86) at 97% identity with BURST using default settings (Al-Ghalith et al, <https://doi.org/10.5281/zenodo.806850>). The generated alignment table was filtered by dropping samples with low depth (<10,000 reads per sample). Functional profiling of the shotgun sequencing data was completed using the KEGG Orthology group annotations for RefSeq-derived genes from direct alignment. KEGG Orthology profiles were also predicted from reference genomes and the predicted profiles were augmented to improve the estimates of low-abundance genes using SHOGUN (<https://github.com/knights-lab/SHOGUN>).

Biopsy samples were sequenced via amplification of the V4 region of the 16S ribosomal RNA gene (Gohl et al., 2016), followed by paired-end 2x250 bp sequencing on an Illumina MiSeq. Adapters were trimmed and low-quality reads (<25 Q-score) were dropped using Shi7 (Al-Ghalith et al., 2018). Amplicon reads were stitched also using Shi7 (Al-Ghalith et al., 2018). Amplicon sequences were aligned to the 16S rRNA genes from the same bacterial genomes in the shotgun sequencing approach using BURST (Al-Ghalith et al, <https://doi.org/10.5281/zenodo.806850>) with the same setting as above.

**Microbiome data analysis**

Downstream analysis of taxa and KEGG Orthology tables was performed in R (R Foundation for Statistical Computing, Vienna, Austria). Computing PERMANOVA, Shannon diversity, and Bray Curtis dissimilarity was done using *adonis*, *diversity*(x, index="shannon"), and *vegdist* (x, method="bray") functions from the *vegan* package. Before testing for taxa differences between the subgroups, taxa were removed that were absent in 90% of the subjects (averaged data excluding flares). To identify differentially abundant features an FDR cutoff of <0.25 was used. In specified cases this was cutoff was made more rigorous post-hoc to display only top features due to the great number of significant changes at FDR < 0.25.

Inter-individual variation was compared to intra-individual variation by comparing the mean of microbiome distances between samples from different individuals with the mean of the distances between samples from each individual.

Bray-Curtis dissimilarity (BCD)-based irregularity (BCDI) was computed by extracting the pairwise dissimilarities between all healthy control (HC) and HC or IBS samples, and the median of these dissimilarities was stored. The 90th percentile of the HC values was used as a cutoff for identifying microbiome samples that were different compared to those of HC. For this analysis samples from one HC subject (10007557) were removed since the median of these samples was above the 90th percentile of the HC BCDI scores. A sensitivity analysis of the 90th percentile cutoff values was performed by randomly drawing one sample per HC subject and identifying the BCDI within these samples 500 times. In addition, the 90th percentile cutoffs from averaged HC microbiome abundances were computed. Using the average did not change the 90th percentile cutoff (0.63).

Time course permutation analysis of BCDI scores was performed by fitting 3rd order polynomial splines to BCDI scores for every subject­. Sum of squares (SS) from the original fit were compared to an ensemble of SS from 999 time-point perturbations.

**Metabolomics**

**1H NMR metabolome profiling of serum and stool samples**

Aliquoted stool samples (~100 mg) were randomized in order and transferred to a screw-cap tube containing 50 mg 1.0 mm Zirconia beads (BioSpec). Metabolites were extracted by addition of 400 µL of acetonitrile:H2O (approximate volumetric ratio of 1:3) and homogenized for 30 seconds in a Biospec beat beater at maximum speed. The homogenized samples were then centrifuged for 20 minutes at 16000 x g, after which the supernatant was transferred to Spin-X 0.22µm spin filter tubes (COSTAR®) and centrifuged for 30 minutes at 16000 x g. 80 µL of the filtered samples was aliquoted into 96 well plates, and 10 µL was kept separately for downstream quality control purposes. Samples were dried under nitrogen flow before reconstituting in 540 µL of D2O and 60 µL of NMR buffer, all in 96 well deep well plates (COSTAR®). The plate was then placed on an Eppendorf MixMate plate shaker at 1300 rpm for 5 minutes. The reconstituted fecal water and buffer mixture was transferred to 5 mm NMR tubes. Plasma buffer with 1.5 M KH2PO4 was prepared by dissolving 20.4g of KH2PO4 in 80mL of D2O. 6 mL of D2O containing 100 mg of 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TSP) (Millipore-Sigma) and 13 mg of NaN3 was added and mixed by shaking and sonication. The pH was adjusted to pH 7.4 with NaOH pellets. Total volume was adjusted with D2O.

Serum samples were thawed and centrifuged at 4°C at 12000 x g for 5 minutes. All samples were kept at -40˚C or colder until analyzed. 90 µL of the supernatant was mixed with 90 µL of plasma buffer before being transferred to a 3 mm NMR tube. Plasma buffer with 0.075 M NaH2PO4 was prepared by dissolving 1.064 g of NaH2PO4 in 80 mL of D2O. 4mL of D2O containing 80 mg of 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TSP) (Millipore-Sigma) and 40 mg of NaN3 was added and mixed by shaking and sonication. The pH was adjusted to pH 7.4 with NaOH pellets. Total volume was adjusted with D2O.

Metabolic profiles were recorded essentially as described previously (Dona et al., 2014) on a Bruker 600 MHz spectrometer (Bruker Biospin) set at a constant temperature of 300K for fecal samples and 310K for plasma samples. A 1D nuclear Overhauser enhancement spectroscopy (NOSEY) experiment and a 2D J-resolved experiment was performed for each fecal and serum sample. A total of 32 scans were acquired with an acquisition time of 4 minutes and 3 seconds per fecal sample following 4 dummy scans and the spectral data was collected into 64K data points. Automatic phasing, baseline correction and spectral calibration to TSP (0 ppm) was performed in Topspin 3.1 (Bruker Biospin).

The pre-processed spectral data was imported into MATLAB (Version 8.3.0.532 R2014a, Mathworks Inc, Natick, MA, USA). A series of in-house scripts were used for the following executions. The spectra were manually aligned to correct for subtle alterations in the chemical shifts of the peaks due to variation in pH. To account for the difference in sample concentration, probabilistic quotient normalization (PQN) was applied to the spectral data. A projection to latent structures-discriminant analysis (PLS-DA) model based on the Monte Carlo cross-validation (MCCV) method was constructed on the complete spectral profiles to identify discriminatory features in relevant comparisons (Garcia-Perez et al., 2017; Posma et al., 2018). A total of 1,000 MCCV models with 25 bootstrap rounds in each model was used to assess model robustness and to calculate the mean prediction (Tpred) of each sample. Discriminatory spectral features were annotated using statistical total correlation spectroscopy (STOCSY) (Cloarec et al., 2005) and a combination of in-house and online databases (www.hmdb.ca). An in-house developed peak integration script was applied to calculate the integral of spectral peaks of interest.

**Bile acid profiling through LC-MS/MS**

Metabolites were extracted as detailed above for 1H NMR**.** Samples were analyzed on an ACQUITY ultraperformance liquid-chromatography (UPLC) system (Waters Ltd., UK) coupled to a Xevo G2-S quadrupole time of flight (Q-TOF) mass spectrometer (Waters Ltd.). A reversed-phase column ACQUITY BEH C8 column (1.7 μm, 100 mm × 2.1 mm) was used at an operating temperature of 60°C. The aqueous part of the mobile phase consisted of 1 mM ammonia acetate in ultrapure water, pH 4.15. The organic mobile phase was 1:1 isopropanol acetonitrile. For detailed description of the experimental methods see (Sarafian et al., 2015).

Data files were imported into MassLynx (Waters Ltd.) where peaks were automatically integrated. Manual inspection on each processed sample file was carried out to ensure that the spectra had been correctly integrated. The extracted peak integral was then normalized to the total ion current (TIC) of each sample.

**SCFA quantification with GC-MS/MS**

Colonic biopsies were stored below -40°C until extraction. Biopsy tissues were transferred to a screw-cap tube and weighed, after which 5 1.0 mm Zirconia beads and 100 µL of ultrapure water were added. The tissue was homogenized in a Biospec bead-beater using two 30 seconds cycles at max speed. An eleven-point calibration curve and a pooled QC sample was constructed using genuine SCFA standards. Metabolites were then extracted using methyl tert-butyl ether (MTBE) (Millipore-Sigma) and derivatized with N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-butyldimethylchloro-silane (MTBSTF + 1% TBDMSCI). Samples were analyzed on a 7000D Triple-Quadrupole Gas chromatography-mass spectrometer (GC-MS) (Agilent Technologies Ltd.).

Data files were imported and analyzed in MassHunter Workstation Software Quantitation Analysis for QQQ version B.07.01 (Agilent Technologies Ltd.). The resulting SCFA concentration were corrected for dilution factor and normalized by sample weight.

**Tryptophan quantification with LC-MS/MS**

Stool was weighed on an analytical balance (sample weights ~50 mg) after which 1 mL of -20°C extraction solvent with internal standards was added to each sample, and sample mixed by vortexing at max speed for 3-5 seconds. Extraction solvent contained 200 ng/mL tryptamine-d4, 500 ng/mL L-tryptophan-d3, 1000 ng/mL 3-methylindole-d3, 200 ng/mL indole-3-acetic acid-d5, 200 ng/mL serotonin-d4 in 80% methanol. Samples were sonicated in a sonication bath at RT for 10 minutes and vortexed. Samples were placed at -80°C for 1 hour to facilitate protein precipitation. Extracts were cleared of debris via centrifugation at 18,000 x g, for 20 minutes at 4°C, and the resulting supernatant was transferred to a new microfuge tube. A quality control sample was prepared by pooling 10 μL of every sample. 100 μL of the sample was transferred to a glass autosampler vial and remaining extracts were stored at -80°C. Standard curves were prepared in 80% methanol in a dilution series from 1000 ng/mL to 0.1 ng/mL.

LC-MS/MS was performed on a Waters Acquity UPLC with T3 C18 stationary phase (1 x 50 mm, 1.7 μM) column coupled to a Waters Xevo TQ-S triple quadrupole mass spectrometer. Mobile phases were 100% methanol (B) and water with 0.1% formic acid (A). The analytical gradient was: 0 min, 5% B; 0.5 min, 5% B; 2.5 min, 95% B; 3.5 min, 95% B; 3.55 min, 5% B; 5 min, 5% B. Flow rate was 350 μL/min with an injection volume of 2.5 μL. Samples were held at 4°C in the autosampler, and the column was operated at 45°C. The MS was operated in selected reaction monitoring (SRM) mode. Product ions, collision energies, and cone voltages were optimized for each analyte by direct injection of individual synthetic standards. Inter-channel delay was set to 3 milliseconds. The MS was operated in positive ionization mode with capillary voltage set to 3.2 kV. Source temperature was 150°C and desolvation temperature at 550°C. Desolvation gas flow was 1000 L/h, cone gas flow was 150 L/h, and argon collision gas flow was 0.2 mL/min. Nebulizer pressure (nitrogen) was set to 7 Bar.

Raw data files were imported into Skyline software (MacLean et al., 2010). Each target analyte was manually inspected for retention time and peak area integration. Peak areas were extracted for target compounds detected in biological samples and normalized to the peak area of the appropriate internal standard or surrogate in each sample. Normalized peak areas were exported to Microsoft excel where concentrations were obtained using the linear regression formulas generated from the calibration curve. Limits of detection (LOD) and limits of quantification (LOQ) were calculated as 3x or 10x the standard deviation of the blank divided by the slope of the calibration curve respectively (Broccardo et al., 2013; Shrivastava and Gupta, 2011). One compound, 3-methyl-indole did not produce a linear response and only raw peak areas are reported for this compound (relative quantification only).

**Metabolomics data analysis**

Metabolomics data was log10 transformed (with pseudo count 1 for zero values) and tested for significance in R with linear mixed-effect models correcting for subject using the *lmer* function from the *lmerTest* package with formula *lmer*(data ~ cohort + (1|subject\_id). Comparison contrasts were extracted using the *get\_contrasts* function from the *psycho* package version 0.4-91, and nominal p-values were adjusted per contrast table using the *p.adjust*(, method="fdr") function. Significance of by subject-averaged data was tested using Mann-Whitney tests using the *wilcox.test* function.

Time-series analysis on NMR data was carried out using the santaR version 1.0 package in R. The analysis was based on 1,000 bootstrap rounds (95% confidence interval), 1,000 permutation rounds and 4 degrees of freedom.

**Cytokine measurements**

Multiplexed Luminex according to manufacturer’s instructions was used for quantification of IL-8, IFNγ, IL-10, Il-18, IL-22, Leptin, VEGF, MIG, IL-1β, IL-17A, IL-1RA, IL-6 & TNFα. The beads were recorded on a Bioplex 200 Luminex instrument. Samples were tested in duplicate and values were quantified by interpolation from a 5 point standard curves. TGFβ-1 was quantified using enzyme-linked immunosorbent assay (ELISA) according to manufacturer’s instructions (R&D Systems, Minneapolis MN). Absorbance was measured on a Bio-Rad 550 microtiter plate reader. Samples were assayed in duplicate and values were interpolated from log-log fitted standard curves.

**RNA sequencing and analysis**

mRNA was extracted from biopsy samples and used for RNA-Seq library preparation following instructions in the Illumina TruSeq RNA Library Prep Kit v2. Sequencing was run on an Illumina High Seq-2000 in the Mayo Clinic Sequencing Core with 101bp paired end reads. Gene expression counts were obtained using the MAP-RSeq v.2.0.0 workflow (Kalari et al., 2014) which is part of the Mayo Bioinformatics Core pipeline. MAP-RSeq consists of alignment with TopHat 2.0.12 (Kim et al., 2013) against the human hg19 genome build and gene counts with the Subread package 1.4.4 (Liao et al., 2019). Gene annotation files were obtained from Ensemble version 75. Gene counts were normalized using RPKM (Reads Per Kilobase per million Mapped reads). Differential expression analysis was performed using edgeR 2.6.2 (Robinson et al., 2010). Pathway enrichment analyses were performed using R package RITAN (Rapid Integration of Term Annotation and Network resources, <https://www.bioconductor.org/packages/release/bioc/html/RITAN.html>).

**Methylome sequencing and analysis**

Illumina Infinium MethylationEPIC BeadChips with ~850K CpG sites were used to assess genome-wide methylation in genomic DNA isolated from biopsy samples. For data pre-processing the raw data (.idat) files were loaded into R package ChAMP version 2.9.10 (Tian et al., 2017). Probes that had detection p-value >0.01, bead count <3, overlapped with SNP sites, or with multiple alignments in the human genome were removed, which resulted in 773,789 CpG sites for downstream analyses. Potential batch effects were corrected by the Combat method (Johnson et al., 2007; Sun et al., 2011). Differentially methylated CpG sites were detected using the *limma* function with Benjamini-Hochberg (BH) multiple testing correction. CpG sites with between-group differential p-value <0.01 and methylation difference greater than 5% were considered as differentially methylated CpGs (DMCs). Clusters within these DMCs (differentially methylated regions (DMRs)) were identified using the Bumphunter algorithm (Jaffe et al., 2012) and defined as a minimum of 4 probes in the region with adjusted DMR p-value <0.05 through permutation test. Genes associated with DMCs or DMRs were used for pathway enrichment analysis with the R package RITAN.

To correct for differences in gender and small numbers of male samples only biopsy samples from female subjects were included for interpretation. We focused our analysis on samples from the first biopsy time point and used time point 2 samples as a verification cohort.

**Multi-omics data integration**

Association between stool microbial features and stool metabolites was investigated using the Maaslin2 package in R (https://huttenhower.sph.harvard.edu/maaslin2). Maaslin2 was ran using minimum abundance and minimum prevalence for microbial features were set at 0.0001 and 0.5 respectively. Threshold for FDR corrected q-value was set at 0.25. Linear mixed effects models were applied to the association with subject set as random-effect.

Identification of structural deletion and variable regions and subsequent association with significant metabolite features was performed as reported in the methods paper (Zeevi et al., 2019). Due to low number of male samples only data from females was included.

Before running correlations, all taxa abundance data was adjusted for compositionality with centered log ratio (CLR) transformation from the *robCompositions* package in R. For correlation networks, species were removed that had a mean per-sample abundance under 0.001%, data was adjusted for compositionality, and each set of significant Spearman correlations were assembled into a network using *igraph* and plotted using *ggraph* in R.

Lasso penalized regression machine learning was performed using a model for regularization and feature selection to integrate host gene expression with microbiome and metabolomics data. Host biopsy gene expression from time point 1, collapsed fecal microbiome abundance and collapsed fecal metabolite data were subject-matched resulting in a subset of 25 IBS patients and 13 healthy controls. The *biomaRt* R package was used to remove non-protein-coding genes, lowly expressed genes (expressed in less than half of the samples), and genes with low variance, resulting in 12132 unique genes. A variance stabilizing transformation was performed on the filtered gene expression data using the *DESeq2* R package. For the microbiome data, the counts taxa matrix was summarized at species, genus, family, and phylum taxonomic levels, and only taxa found at 0.01% relative abundance in at least 20% of the samples were kept. This filtered taxon matrix was CLR transformed. The fecal metabolomic data, NMR metabolites, bile acids, and tryptophan panel data was concatenated, and log2 transformed.

The Lasso regression model was fit separately in order to identify gene-microbiome and gene-metabolite associations. The gene-wise model uses gene expression for each gene as response and microbiome abundance or metabolite concentrations as predictors. The effect of gender and IBS-subtype was controlled for by including them as binary covariates in our predictor matrix. Leave-one-out cross validation was used for tuning the penalty parameters in the Lasso model fits using the R package *glmnet*. Inference for Lasso models was performed using regularized projections to obtain significance and confidence interval for each variable associated with a given gene. Multiple hypothesis testing was corrected for using the Benjamini-Hochberg method. Since the Lasso model is sensitive to small variations of the predictor, we used stability selection to select robust variables associated with the host genes. Intersects of outputs from Lasso and stability selection models were inspected and filtered at FDR <0.1. Host gene-gender and host gene-IBS subtype associations were removed.

**In vitro and in vivo hypoxanthine consumption experiments**

Bacteria were cultivated in Mega medium (Romano et al., 2015). After overnight growth, hypoxanthine levels in the culture supernatant were determined using LC-MS. Hypoxanthine identity was verified through matching of accurate mass and retention time of an authentic standard (Sigma-Aldrich).

Monocolonization experiments were performed on 6-week old germ-free Swiss Webster mice. Three female mice were orally gavaged with ~2\*106 CFU of overnight bacterial culture grown in BHI medium + 0.01% cysteine and co-housed for the duration of the experiment. Hypoxanthine (Sigma-Aldrich) was supplied at 100 μM in filter sterilized NANOpure water. Water consumption was monitored and not different between the groups. On day 4 after gavage mice were sacrificed and cecal contents were collected.

The combined hypoxanthine and xanthine concentration was determined in cecal contents using Amplex™ Red Xanthine/Xanthine Oxidase Assay Kit (Thermo Fisher). Sample weights were normalized by addition of H2O and samples were homogenized by beat beating. Metabolites were extracted by addition of 19 volumes of 80°C ultrapure H2O and incubation at 80°C for 3 minutes while shaking at 800 rpm in a heating block. The supernatant after centrifugation for 10 minutes at 4°C served as the metabolite sample. Samples were analyzed in duplicate for 30 minutes and normalized based on parallel reactions without XO enzyme to correct for baseline levels of H2O2 in the sample.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Details on statistical tests, n numbers, and significance cutoffs can be found in the figure legends. When relevant, further details are found in the method details for the specific measurement.

**Supplementary Excel Table Titles**

* **Table S1.** Sample metadata including number of samples, daily stool diary, and dietary information, Related to Figure 1
* **Table S2.** All results from taxa comparisons, Related to Figure 1
* **Table S3.** All results from metagenomic KO term comparisons, Related to Figure 3
* **Table S4.** Multi omics associations; KEGG module - taxa correlations, Maaslin results of microbial taxa associated to IBS-related metabolites, Spearman correlations ofBSS and pain with other omics datasets, andstructural genomics variation of microbiome that correlating to IBS metabolites, Related to Figure 4
* **Table S5.** Personalized flare results, Related to Figure 5
* **Table S6.** Differentially expressed and methylated genes, Related to Figure 7
* **Table S7.** Gene-taxa and gene-metabolite correlations using correlation networks and Lasso regression, Related to Figure 6

**References**

Al-Ghalith, G.A., Hillmann, B., Ang, K., Shields-Cutler, R., and Knights, D. (2018). SHI7 Is a Self-Learning Pipeline for Multipurpose Short-Read DNA Quality Control. mSystems *3*.

Becker, M.A., Schumacher, H.R., MacDonald, P.A., Lloyd, E., and Lademacher, C. (2009). Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol *36*, 1273-1282.

Bhattarai, Y., Muniz Pedrogo, D.A., and Kashyap, P.C. (2017a). Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol *312*, G52-G62.

Bhattarai, Y., Schmidt, B.A., Linden, D.R., Larson, E.D., Grover, M., Beyder, A., Farrugia, G., and Kashyap, P.C. (2017b). Human-derived gut microbiota modulates colonic secretion in mice by regulating 5-HT3 receptor expression via acetate production. Am J Physiol Gastrointest Liver Physiol *313*, G80-G87.

Bhattarai, Y., Williams, B.B., Battaglioli, E.J., Whitaker, W.R., Till, L., Grover, M., Linden, D.R., Akiba, Y., Kandimalla, K.K., Zachos, N.C.*, et al.* (2018). Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion. Cell Host Microbe *23*, 775-785 e775.

Biaggioni, I., Freeman, R., Mathias, C.J., Low, P., Hewitt, L.A., Kaufmann, H., and Droxidopa, I. (2015). Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension *65*, 101-107.

Broccardo, C.J., Schauer, K.L., Kohrt, W.M., Schwartz, R.S., Murphy, J.P., and Prenni, J.E. (2013). Multiplexed analysis of steroid hormones in human serum using novel microflow tile technology and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci *934*, 16-21.

Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., and Madden, T.L. (2009). BLAST+: architecture and applications. BMC Bioinformatics *10*, 421.

Camilleri, M. (2014). Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol *8*, 49-61.

Chiaro, T.R., Soto, R., Zac Stephens, W., Kubinak, J.L., Petersen, C., Gogokhia, L., Bell, R., Delgado, J.C., Cox, J., Voth, W.*, et al.* (2017). A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. Sci Transl Med *9*.

Cloarec, O., Dumas, M.E., Craig, A., Barton, R.H., Trygg, J., Hudson, J., Blancher, C., Gauguier, D., Lindon, J.C., Holmes, E.*, et al.* (2005). Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem *77*, 1282-1289.

Crouzet, L., Gaultier, E., Del'Homme, C., Cartier, C., Delmas, E., Dapoigny, M., Fioramonti, J., and Bernalier-Donadille, A. (2013). The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil *25*, e272-282.

De Palma, G., Lynch, M.D., Lu, J., Dang, V.T., Deng, Y., Jury, J., Umeh, G., Miranda, P.M., Pigrau Pastor, M., Sidani, S.*, et al.* (2017). Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med *9*.

Dona, A.C., Jimenez, B., Schafer, H., Humpfer, E., Spraul, M., Lewis, M.R., Pearce, J.T., Holmes, E., Lindon, J.C., and Nicholson, J.K. (2014). Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal Chem *86*, 9887-9894.

Duan, R., Zhu, S., Wang, B., and Duan, L. (2019). Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review. Clin Transl Gastroenterol *10*, e00012.

Edogawa, S., Edwinson, A.L., Peters, S.A., Chikkamenahalli, L.L., Sundt, W., Graves, S., Gurunathan, S.V., Breen-Lyles, M., Johnson, S., Dyer, R.*, et al.* (2019). Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Gut.

Garcia-Perez, I., Posma, J.M., Gibson, R., Chambers, E.S., Hansen, T.H., Vestergaard, H., Hansen, T., Beckmann, M., Pedersen, O., Elliott, P.*, et al.* (2017). Objective assessment of dietary patterns by use of metabolic phenotyping: a randomised, controlled, crossover trial. Lancet Diabetes Endocrinol *5*, 184-195.

Gohl, D.M., Vangay, P., Garbe, J., MacLean, A., Hauge, A., Becker, A., Gould, T.J., Clayton, J.B., Johnson, T.J., Hunter, R.*, et al.* (2016). Systematic improvement of amplicon marker gene methods for increased accuracy in microbiome studies. Nat Biotechnol *34*, 942-949.

Grimble, G.K. (1994). Dietary nucleotides and gut mucosal defence. Gut *35*, S46-51.

Jaffe, A.E., Murakami, P., Lee, H., Leek, J.T., Fallin, M.D., Feinberg, A.P., and Irizarry, R.A. (2012). Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol *41*, 200-209.

Jepps, T.A., Greenwood, I.A., Moffatt, J.D., Sanders, K.M., and Ohya, S. (2009). Molecular and functional characterization of Kv7 K+ channel in murine gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol *297*, G107-115.

Johnson, W.E., Li, C., and Rabinovic, A. (2007). Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics *8*, 118-127.

Kalari, K.R., Nair, A.A., Bhavsar, J.D., O'Brien, D.R., Davila, J.I., Bockol, M.A., Nie, J., Tang, X., Baheti, S., Doughty, J.B.*, et al.* (2014). MAP-RSeq: Mayo Analysis Pipeline for RNA sequencing. BMC Bioinformatics *15*, 224.

Kanemitsu, T., Tsurudome, Y., Kusunose, N., Oda, M., Matsunaga, N., Koyanagi, S., and Ohdo, S. (2017). Periodic variation in bile acids controls circadian changes in uric acid via regulation of xanthine oxidase by the orphan nuclear receptor PPARalpha. J Biol Chem *292*, 21397-21406.

Kashyap, P.C., Marcobal, A., Ursell, L.K., Larauche, M., Duboc, H., Earle, K.A., Sonnenburg, E.D., Ferreyra, J.A., Higginbottom, S.K., Million, M.*, et al.* (2013). Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology *144*, 967-977.

Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol *14*, R36.

Lee, J.S., Wang, R.X., Alexeev, E.E., Lanis, J.M., Battista, K.D., Glover, L.E., and Colgan, S.P. (2018). Hypoxanthine is a checkpoint stress metabolite in colonic epithelial energy modulation and barrier function. J Biol Chem *293*, 6039-6051.

Lee, J.S., Wang, R.X., Goldberg, M.S., Clifford, G.P., Kao, D.J., and Colgan, S.P. (2020). Microbiota-Sourced Purines Support Wound Healing and Mucous Barrier Function. iScience *23*, 101226.

Liao, Y., Smyth, G.K., and Shi, W. (2019). The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res *47*, e47.

MacLean, B., Tomazela, D.M., Shulman, N., Chambers, M., Finney, G.L., Frewen, B., Kern, R., Tabb, D.L., Liebler, D.C., and MacCoss, M.J. (2010). Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics *26*, 966-968.

Matsumoto, M., Ooga, T., Kibe, R., Aiba, Y., Koga, Y., and Benno, Y. (2017). Colonic Absorption of Low-Molecular-Weight Metabolites Influenced by the Intestinal Microbiome: A Pilot Study. Plos One *12*, e0169207.

Mete, R., Tulubas, F., Oran, M., Yilmaz, A., Avci, B.A., Yildiz, K., Turan, C.B., and Gurel, A. (2013). The role of oxidants and reactive nitrogen species in irritable bowel syndrome: a potential etiological explanation. Med Sci Monit *19*, 762-766.

Moreau, B., Clement, P., Theoret, Y., and Seidman, E.G. (2017). Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD. Therap Adv Gastroenterol *10*, 819-827.

Peters, S.A., Edogawa, S., Sundt, W.J., Dyer, R.B., Dalenberg, D.A., Mazzone, A., Singh, R.J., Moses, N., Smyrk, T.C., Weber, C.*, et al.* (2017). Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function. Am J Gastroenterol *112*, 913-923.

Pittayanon, R., Lau, J.T., Yuan, Y., Leontiadis, G.I., Tse, F., Surette, M., and Moayyedi, P. (2019). Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology *157*, 97-108.

Posma, J.M., Garcia-Perez, I., Ebbels, T.M.D., Lindon, J.C., Stamler, J., Elliott, P., Holmes, E., and Nicholson, J.K. (2018). Optimized Phenotypic Biomarker Discovery and Confounder Elimination via Covariate-Adjusted Projection to Latent Structures from Metabolic Spectroscopy Data. J Proteome Res *17*, 1586-1595.

Poyet, M., Groussin, M., Gibbons, S.M., Avila-Pacheco, J., Jiang, X., Kearney, S.M., Perrotta, A.R., Berdy, B., Zhao, S., Lieberman, T.D.*, et al.* (2019). A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research. Nat Med *25*, 1442-1452.

Reigstad, C.S., Salmonson, C.E., Rainey, J.F., 3rd, Szurszewski, J.H., Linden, D.R., Sonnenburg, J.L., Farrugia, G., and Kashyap, P.C. (2015). Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J *29*, 1395-1403.

Roager, H.M., Hansen, L.B.S., Bahl, M.I., Frandsen, H.L., Carvalho, V., Gobel, R.J., Dalgaard, M.D., Plichta, D.R., Sparholt, M.H., Vestergaard, H.*, et al.* (2016). Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nat Microbiol *1*.

Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics *26*, 139-140.

Romano, K.A., Vivas, E.I., Amador-Noguez, D., and Rey, F.E. (2015). Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio *6*, e02481.

Saffouri, G.B., Shields-Cutler, R.R., Chen, J., Yang, Y., Lekatz, H.R., Hale, V.L., Cho, J.M., Battaglioli, E.J., Bhattarai, Y., Thompson, K.J.*, et al.* (2019). Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun *10*, 2012.

Sarafian, M.H., Lewis, M.R., Pechlivanis, A., Ralphs, S., McPhail, M.J., Patel, V.C., Dumas, M.E., Holmes, E., and Nicholson, J.K. (2015). Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem *87*, 9662-9670.

Shrivastava, A., and Gupta, V. (2011). Methods for the determination of limit of detection and limit of quantitation of the analytical methods. Chronicles of Young Scientists *2*, 21-25.

Sun, Z., Chai, H.S., Wu, Y., White, W.M., Donkena, K.V., Klein, C.J., Garovic, V.D., Therneau, T.M., and Kocher, J.P. (2011). Batch effect correction for genome-wide methylation data with Illumina Infinium platform. BMC Med Genomics *4*, 84.

Tian, Y., Morris, T.J., Webster, A.P., Yang, Z., Beck, S., Feber, A., and Teschendorff, A.E. (2017). ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics *33*, 3982-3984.

Touw, K., Ringus, D.L., Hubert, N., Wang, Y., Leone, V.A., Nadimpalli, A., Theriault, B.R., Huang, Y.E., Tune, J.D., Herring, P.B.*, et al.* (2017). Mutual reinforcement of pathophysiological host-microbe interactions in intestinal stasis models. Physiol Rep *5*.

Vazquez-Roque, M.I., Camilleri, M., Smyrk, T., Murray, J.A., O'Neill, J., Carlson, P., Lamsam, J., Eckert, D., Janzow, D., Burton, D.*, et al.* (2012). Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol *303*, G1262-1269.

Zeevi, D., Korem, T., Godneva, A., Bar, N., Kurilshikov, A., Lotan-Pompan, M., Weinberger, A., Fu, J., Wijmenga, C., Zhernakova, A.*, et al.* (2019). Structural variation in the gut microbiome associates with host health. Nature *568*, 43-48.